Prevalence of MET exon 14-mutations or MET amplification in non-small cell lung cancer in Swiss patients

被引：0
|
作者：
Prince, S. Savic [1 ]
Bihl, M. [1 ]
Eppenberger-Castori, S. [1 ]
Matter, M. S. [1 ]
Zellweger, N. [2 ]
Rothschild, S. I. [2 ]
Bubendorf, L. [1 ]
机构：
[1] Univ Hosp Basel, Inst Med Genet & Pathol, Pathol, Basel, Switzerland
[2] Univ Hosp Basel, Dept Oncol, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4P
引用
收藏
页码：S700 / S700
页数：1
相关论文
共 50 条
  • [21] The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis
    Zhu, Y.
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhuang, W.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 5 - 5
  • [22] Retrospective Analysis to Optimize the Detection of MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer
    Lu, Jang-Jih
    Tsai, Shu-Hui
    Lin, Lee-Chung
    Chiueh, Tzong-Shi
    DIAGNOSTICS, 2024, 14 (11)
  • [23] MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non -small cell lung cancer?
    Pruis, Melinda A.
    von der Thusen, Jan H.
    Dubbink, Hendrikus Jan
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (22)
  • [24] Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress
    Paik, P.
    Sakai, H.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Felip, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
    Wu, Yi-Long
    Smit, Egbert F.
    Bauer, Todd M.
    CANCER TREATMENT REVIEWS, 2021, 95
  • [26] Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Paik, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina C.
    Mazieres, Julien
    Viteri, Santiago
    Senellart, Helene
    Van Meerbeeck, Jan
    Raskin, Jo
    Reinmuth, Niels
    Conte, Pierfranco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Patel, Jyoti D.
    Horn, Leora
    Griesinger, Frank
    Han, Ji-Youn
    Kim, Young-Chul
    Chang, Gee-Chen
    Tsai, Chen-Liang
    Yang, James C. -H.
    Chen, Yuh-Min
    Smit, Egbert F.
    van der Wekken, Anthonie J.
    Kato, Terufumi
    Juraeva, Dilafruz
    Stroh, Christopher
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Heymach, John V.
    Le, Xiuning
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10): : 931 - 943
  • [27] Prevalence of MET amplification, MET expression, and MET-related genomic alterations in non-small cell lung cancer (NSCLC)
    Ang, A. L.
    Yang, H.
    Anderson, A. A.
    Tang, R.
    Damore, M. A.
    Loberg, R. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 161 - 162
  • [28] MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
    Ramesh, Shrey
    Cifci, Ahmet
    Javeri, Saahil
    Minne, Rachel L.
    Longhurst, Colin A.
    Nickel, Kwangok P.
    Kimple, Randall J.
    Baschnagel, Andrew M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1379 - 1390
  • [29] A MET Inhibitor in the Treatment of Metastatic Non-Small Cell Lung Cancer with MET Amplification
    Zhang, Tongtong
    Li, Junling
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1276 - S1276
  • [30] Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
    Cortot, Alexis
    Le, Xiuning
    Smit, Egbert
    Viteri, Santiago
    Kato, Terufumi
    Sakai, Hiroshi
    Park, Keunchil
    Camidge, D. Ross
    Berghoff, Karin
    Vlassak, Soetkin
    Paik, Paul K.
    CLINICAL LUNG CANCER, 2022, 23 (03) : 195 - 207
12345